2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazo le: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients

Department of Pharmacology, Tohoku University, Miyagi, Japan
Journal of Nuclear Medicine (Impact Factor: 5.56). 04/2007; 48(4):553-61. DOI: 10.2967/jnumed.106.037556
Source: PubMed

ABSTRACT Extensive deposition of dense amyloid fibrils is a characteristic neuropathologic hallmark in Alzheimer's disease (AD). Noninvasive detection of these molecules is potentially useful for early and precise detection of patients with AD. This study reports a novel compound, 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole (BF-227), for in vivo detection of dense amyloid deposits using PET.
The binding affinity of BF-227 to amyloid-beta (Abeta) fibrils was calculated. The binding property of BF-227 to amyloid plaques was evaluated by neuropathologic staining of AD brain sections. Brain uptake and in vivo binding of BF-227 to Abeta deposits were also evaluated using mice. For clinical evaluation of (11)C-BF-227 as a PET probe, 11 normal (healthy) subjects and 10 patients with AD participated in this study. Dynamic PET images were obtained for 60 min after administration of (11)C-BF-227. The regional standardized uptake value (SUV) and the ratio of regional to cerebellar SUV were calculated as an index of (11)C-BF-227 retention. The regional tracer distribution in AD patients was statistically compared with that of aged normal subjects on a voxel-by-voxel basis.
BF-227 displayed high binding affinity to synthetic Abeta1-42 fibrils (K(i) [inhibition constant], 4.3 +/- 1.5 nM). Neuropathologic staining has demonstrated preferential binding of this agent to dense amyloid deposits in AD brain. Moreover, a biodistribution study of this agent revealed excellent brain uptake and specific labeling of amyloid deposits in transgenic mice. The present clinical PET study using (11)C-BF-227 demonstrated the retention of this tracer in cerebral cortices of AD patients but not in those of normal subjects. All AD patients were clearly distinguishable from normal individuals using the temporal SUV ratio. Voxel-by-voxel analysis of PET images revealed that cortical BF-227 retention in AD patients is distributed primarily to the posterior association area of the brain and corresponded well with the preferred site for neuritic plaque depositions containing dense Abeta fibrils.
These findings suggest that BF-227 is a promising PET probe for in vivo detection of dense amyloid deposits in AD patients.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: 2-Methyl-1,3-thiazole, 2,4-dimethyl-1,3-thiazole, 2,4,5-trimethyl-1,3-thiazole, 2,4,5-trimethyl-1,3-oxazole, 2-methyl-1,3-benzoxazole and 2-methyl-1,3-benzothiazole were each treated with benzoyl chloride in acetonitrile containing triethylamine to give the corresponding (Z)-2-(heterocyclic)-1-phenylvinyl benzoates. Base hydrolysis of these vinyl benzoates gave the corresponding 2-(heterocyclic)-1-phenylethenols, which exist in both keto and enol tautomeric forms. These tautomers were used as starting materials for the syntheses of fused-ring heterocycles. The reactivity of the keto-enol tautomers depends on the nature of the heteroatom and the substituents that are present on the ring. Each tautomeric pair reacts with dimethyl acetylenedicarboxylate (DMAD) in methanol to give the 5,6-ring-fused 8-benzoyl-5-oxo-5H-thiazolo- and 8-benzoyl-5-oxo-5H-oxazolopyridinecarboxylate, 4-benzoyl-1-oxo-1H-pyrido[2,1-b]benzoxazolecarboxylate and 4-benzoyl-1oxo-1H-pyrido[2,1-b]benzothiazolecarboxylate derivatives. Two novel 5,7-ring-fused compounds, tetramethyl 9-benzoyl-2,3-dimethyl-5,6-dihydrothiazolo[3,2-a]azepine-5,6,7,8-tetracarboxylate and its oxazole analogue, were also obtained when the tautomers formed from 2,4,5-trimethyl-1,3-thiazole and 2,4,5-trimethyl-1,3-oxazole, respectively, were treated with DMAD. Reactions of the tautomers with methyl propiolate did not, however, give satisfactory results.
    Synthesis 10/2012; 44(21):3337-3352. DOI:10.1055/s-0032-1316790 · 2.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alpha-synuclein (α-syn) aggregation is a neuropathological hallmark of many neurodegenerative diseases, collectively termed synucleinopathies. There is currently no pre-mortem diagnosis tool for these diseases. Although some compounds have been described as potential ligands for α-syn aggregates, no specific PET radiotracer of aggregated α-syn is currently available. Recently, [18F]BF227 has been proposed as an α-syn PET radiotracer in the absence of other specific candidates. We proposed here, for the first time, to use this radiotracer in an accelerated mouse model of synucleinopathy presenting α-syn depositions in brainstem and thalamus. Our in vivo and in vitro studies showed that [18F]BF227 does not bind to α-syn aggregates. These results highlight the fact that [18F]BF227 PET has no suitable characteristics for monitoring this experimental synucleinopathy, justifying the need to develop alternative α-syn PET radiotracers.
    Current Alzheimer research 10/2014; · 3.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In vivo imaging of β-amyloid (Aβ) plaques by non-invasive techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) may facilitate early diagnosis and drug discovery for the treatment of Alzheimer's disease (AD). SPECT is known as a more useful modality than PET in terms of routine diagnostic use, but there have been no reports on attractive probes in clinical studies. In this study, we synthesized and evaluated novel 123I-labeled pyridyl benzoxazole (PBOX) derivatives as SPECT probes for imaging Aβ plaques in vivo. The PBOX derivatives showed affinity for Aβ(1–42) aggregates in vitro (Ki = 6.9–138 nM). In biodistibution experiments in normal mice, all these derivatives showed high initial uptake into (4.6–6.6% ID g−1 at 2 min) and rapid clearance (0.3–1.3% ID g−1 at 60 min) from the brain. Furthermore, [125I]9 clearly labeled Aβ plaques in in vitro autoradiography of postmortem AD brain sections. SPECT/CT study with [123I]9 displayed higher radioactivity in Tg2576 mice than wild-type mice. In addition, ex vivo autoradiograms of brain sections from Tg2576 mice after the injection of [123I]9 showed selective binding of Aβ plaques. In conclusion, [123I]9 may be a potential SPECT probe for imaging Aβ plaques in AD brain.
    RSC Advances 12/2014; 5(2). DOI:10.1039/C4RA10742J · 3.71 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014